Short Interest in PDS Biotechnology Co. (NASDAQ:PDSB) Rises By 15.2%

PDS Biotechnology Co. (NASDAQ:PDSB – Get Rating) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,820,000 shares, a growth of 15.2% from the February 13th total of 1,580,000 shares. Based on an average trading volume of 606,100 shares, the days-to-cover ratio is currently 3.0 days.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on PDSB shares. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Tuesday, February 28th. Noble Financial lifted their price target on shares of PDS Biotechnology to $19.00 in a research report on Monday, November 28th. Finally, B. Riley lifted their price target on shares of PDS Biotechnology from $10.00 to $12.00 in a research report on Wednesday, December 28th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, PDS Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $16.80.

PDS Biotechnology Trading Up 2.9 %

PDS Biotechnology stock opened at $7.00 on Wednesday. The firm’s 50 day moving average price is $8.73 and its two-hundred day moving average price is $7.16. PDS Biotechnology has a 1 year low of $2.89 and a 1 year high of $13.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 15.37 and a current ratio of 15.37. The firm has a market cap of $199.22 million, a price-to-earnings ratio of -6.93 and a beta of 2.31.

Hedge Funds Weigh In On PDS Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Knightsbridge Asset Management LLC boosted its stake in PDS Biotechnology by 101.7% in the 2nd quarter. Knightsbridge Asset Management LLC now owns 44,362 shares of the company’s stock worth $162,000 after purchasing an additional 22,370 shares during the period. Andesa Financial Management Inc. boosted its stake in PDS Biotechnology by 100.0% in the 3rd quarter. Andesa Financial Management Inc. now owns 25,000 shares of the company’s stock worth $74,000 after purchasing an additional 12,500 shares during the period. Virtu Financial LLC acquired a new position in PDS Biotechnology in the 2nd quarter worth approximately $173,000. Amussen Hunsaker Associates LLC acquired a new position in PDS Biotechnology in the 2nd quarter worth approximately $273,000. Finally, Rockefeller Capital Management L.P. acquired a new position in PDS Biotechnology in the 4th quarter worth approximately $45,000. Institutional investors and hedge funds own 18.21% of the company’s stock.

About PDS Biotechnology

(Get Rating)

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection.